Literature DB >> 32414021

Are the Objectives Proposed by the WHO for Routine Measles Vaccination Coverage and Population Measles Immunity Sufficient to Achieve Measles Elimination from Europe?

Pedro Plans-Rubió1,2.   

Abstract

Background: The World Health Organization (WHO) proposed two-dose measles vaccination coverage of at least 95% of the population and percentages of measles immunity in the population of 85%-95% in order to achieve measles elimination in Europe. The objectives of this study were: (1) to determine the measles vaccination coverage required to establish herd immunity against measles viruses with basic reproduction numbers (Ro) ranging from 6 to 60, and (2) to assess whether the objectives proposed by the WHO are sufficient to establish herd immunity against measles viruses.
Methods: The herd immunity effects of the recommended objectives were assessed by considering the prevalence of protected individuals required to establish herd immunity against measles viruses with Ro values ranging from 6 to 60.
Results: The study found that percentages of two-dose measles vaccination coverage from 88% to 100% could establish herd immunity against measles viruses with Ro from 6 to 19, assuming 95% measles vaccination effectiveness. The study found that the objective of 95% for two-dose measles vaccination coverage proposed by the WHO would not be sufficient to establish herd immunity against measles viruses with Ro ≥ 10, assuming 95% measles vaccination effectiveness. By contrast, a 97% measles vaccination coverage objective was sufficient to establish herd immunity against measles viruses, with Ro values from 6 to 13. Measles immunity levels recommended in individuals aged 1-4 years (≥85%) and 5-9 years (≥90%) might not be sufficient to establish herd immunity against most measles viruses, while those recommended in individuals aged 10 or more years (≥95%) could be sufficient to establish herd immunity against measles viruses with Ro values from 6 to 20.
Conclusion: To meet the goal of measles elimination in Europe, it is necessary to achieve percentages of two-dose measles vaccination coverage of at least 97%, and measles immunity levels in children aged 1-9 years of at least 95%.

Entities:  

Keywords:  herd immunity; immunity; measles; measles elimination; measles prevention; measles vaccination coverage objectives; population measles immunity objectives; vaccination

Year:  2020        PMID: 32414021     DOI: 10.3390/vaccines8020218

Source DB:  PubMed          Journal:  Vaccines (Basel)        ISSN: 2076-393X


  8 in total

1.  One single-center serological survey on measles, rubella and mumps antibody levels of people in Youyang, China.

Authors:  Qing Wang; Xiaoping Cheng; Dandan Liu; Changhui Chen; Kaihu Yao
Journal:  Hum Vaccin Immunother       Date:  2021-10-08       Impact factor: 4.526

2.  The measles outbreak in Israel in 2018-19: lessons for COVID-19 pandemic.

Authors:  Chen Stein-Zamir; Hagai Levine
Journal:  Hum Vaccin Immunother       Date:  2021-01-22       Impact factor: 3.452

3.  Humoral Immunity against Measles in Mother-Infant Pairs during the First Year of Life in Greece: A Cross-Sectional Study.

Authors:  Florentia Kanakoudi-Tsakalidou; Evangelia Farmaki; Eleni Papadimitriou; Anna Taparkou; Eleni Agakidou; Styliani Glykou; Fotiοs Papachristou
Journal:  Vaccines (Basel)       Date:  2021-02-10

Review 4.  Status: nosocomial transmission and prevention of SARS-CoV-2 in a Danish context.

Authors:  Henrik Pierre Calum; Louise Palasin Sode; Michael Pedersen
Journal:  APMIS       Date:  2021-07       Impact factor: 3.428

Review 5.  Insights into COVID-19 Vaccine Development Based on Immunogenic Structural Proteins of SARS-CoV-2, Host Immune Responses, and Herd Immunity.

Authors:  Jitendra Kumar Chaudhary; Rohitash Yadav; Pankaj Kumar Chaudhary; Anurag Maurya; Nimita Kant; Osamah Al Rugaie; Hoineiting Rebecca Haokip; Deepika Yadav; Rakesh Roshan; Ramasare Prasad; Apurva Chatrath; Dharmendra Singh; Neeraj Jain; Puneet Dhamija
Journal:  Cells       Date:  2021-10-29       Impact factor: 6.600

6.  Gender differences in measles incidence rates in a multi-year, pooled analysis, based on national data from seven high income countries.

Authors:  Manfred S Green; Naama Schwartz; Victoria Peer
Journal:  BMC Infect Dis       Date:  2022-04-11       Impact factor: 3.090

7.  Vaccination Coverage for Routine Vaccines and Herd Immunity Levels against Measles and Pertussis in the World in 2019.

Authors:  Pedro Plans-Rubió
Journal:  Vaccines (Basel)       Date:  2021-03-13

8.  Seroprevalence of Measles and Mumps Antibodies Among Individuals With Cancer.

Authors:  Sara R Marquis; Jennifer K Logue; Helen Y Chu; Tillie Loeffelholz; Z Z Quinn; Catherine Liu; F Marc Stewart; Paul A Carpenter; Steven A Pergam; Elizabeth M Krantz
Journal:  JAMA Netw Open       Date:  2021-07-01
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.